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AbstrACt
Objectives The aim of this study is to collate multi-
institutional data to determine the value by defining the 
diagnostic performance of fluorodeoxyglucose positron 
emission tomography (FDG PET)/CT for malignancy in 
patients undergoing surgery with an anterior mediastinal 
mass in order to ascertain the clinical utility of PET/CT to 
differentiate malignant from benign aetiologies in patients 
presenting with an anterior mediastinal mass
setting DECiMaL Study is a multicentre, retrospective, 
collaborative cohort study in seven UK surgical sites.
Participants Between January 2002 and June 2015, 
a total of 134 patients were submitted with a mean age 
(SD) of 55 years (16) of which 69 (51%) were men. We 
included all patients undergoing surgery who presented 
with an anterior mediastinal mass and underwent PET/CT. 
PET/CT was considered positive for any reported avidity 
as stated in the official report and the reference was the 
resected specimen reported by histopathology using WHO 
criteria.
Primary and secondary outcome measures Sensitivity, 
specificity, positive and negative predicted values of [18F]-
FDG PET in determining malignant aetiology for an anterior 
mediastinal mass.
results The sensitivity and specificity of PET/CT to 
correctly classify malignant disease were 83% (95% CI 
74 to 89) and 58% (95% CI 37 to 78). The positive and 
negative predictive values were 90% (95% CI 83% to 
95%) and 42% (95% CI 26% to 61%).
Conclusions The results of our study suggest reasonable 
sensitivity but no specificity implying that a negative 
PET/CT is useful to rule out the diagnosis of malignant 
disease whereas a positive result has no value in the 
discrimination between malignant and benign diseases of 
the anterior mediastinum.
IntrOduCtIOn 
Abnormalities in the anterior mediastinum 
are often discovered as an incidental finding. 
When detected, they often present as a diag-
nostic challenge as few radiological features 
are sufficiently discriminatory to guide clini-
cians on the best course of management. One 
of the principal considerations is the proba-
bility of malignancy, as the perceived risk of 
cancer guides the recommendation for inva-
sive tissue sampling or excision. Although 
positron emission tomography (PET)/CT is 
widely used in this regard, little is known on 
the diagnostic and clinical test performance 
of 18 F fluorodeoxyglucose ([18F]-FDG) 
PET-CT as no large published series have 
been reported in the literature.
The aim of our study was to determine the 
diagnostic accuracy by defining the sensitivity 
and specificity of 18FDG PET-CT scans to 
strengths and limitations of this study
 ► To our knowledge, this is the largest study to date 
(essential to ensure narrow CIs for estimates) 
versing this subject.
 ► We were able to obtain an estimate of test 
performance relatively quickly through an 
established research collaborative.
 ► The study did not include the entire spectrum of the 
anterior mediastinal masses, in particular the small 
masses that were only kept under surveillance or 
discharged.
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identify malignancy in patients who have presented with 
an anterior mediastinal mass.
MethOds
We conducted a UK-wide multicentre retrospective 
study under the auspices of the UK Thoracic Surgery 
Research Collaborative. Formal application was made 
to the Research Ethics Committee (15/SS/0185) and 
the outcome was that the study did not require National 
Health Service ethics review.
We included patients who have undergone surgery for 
an anterior mediastinal abnormality and received 18FDG 
PET-CT as part of their preoperative workup. We excluded 
patients in whom a formal histological diagnosis was not 
obtained or did not have a formal 18FDG PET-CT report.
Consecutive patients from January 2002 to June 2015 
were identified from seven participating institutions of 
the UK Thoracic Surgery Research Collaborative through 
interrogation of electronic records. As a pragmatic 
study, the index test of 18FDG PET-CT was conducted 
by consultant radiologists and nuclear medicine physi-
cians according to UK Royal College of Radiologists 
recommendations.1 A positive test result was defined as a 
formally worded ‘positive’ uptake for the anterior medi-
astinal mass. The reference standard was the histology of 
the resected anterior mediastinal mass as conducted by 
pathologists in accordance with the UK Royal College of 
Pathologists guidelines and reported according to WHO 
criteria. Malignancy was defined in accordance with what 
would influence surgical management including thymic 
carcinoma, thymoma, lymphoma and any other malig-
nant tumours, and the following diseases were classified 
as non-malignant: thymic hyperplasia, thymic cyst and ‘no 
malignancy’ per histology report.
As the study was undertaken retrospectively, we 
assumed the results of the histopathology (reference 
test) would not be available for the readers of the 18FDG 
PET-CT (index test) as surgical resection only occurs after 
the preoperative investigations. We also have no reason to 
believe that the reporting pathologists would have access 
Figure 1 Flow diagram. STARD, Standards for Reporting Diagnostic Accuracy; PET, positron emission tomography. 
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to the preoperative 18FDG PET-CT reports (although they 
may have had access to this information on the request 
forms).
Categorical data were summarised as frequency (%), 
continuous data summarised as mean (SD) or median 
(IQR) as appropriate to the data distribution. The primary 
outcome is the calculated sensitivity, specificity, and posi-
tive and negative predictive values with corresponding 
95% CIs. We specified a priori estimates around 50% 
would be considered none, around 75% moderate and 
around 100% to have excellent clinical test performance 
and favour interpretation on sensitivity and specificity 
(considered robust estimates) rather than positive or 
negative predictive values (that can be altered by disease 
prevalence). We also conducted secondary analysis of 
receiver operating characteristic (ROC) curve analyses to 
explore the influence of SUVmax (where available) on 
the diagnosis of malignancy.
We estimated a sample size of 70 patients based on esti-
mated sensitivity of 0.90 with a lowest acceptable CI of 
0.75 using sample size calculations detailed by Flahault 
et al.2 Statistical analyses were conducted on Stata V.13 
(College Station, Texas, USA).
results
From January 2002 to June 2015, a total of 672 patients 
were included of which 521 were excluded due to not 
having a PET-CT and 17 excluded due to not having 
radiology report, leaving 134 patients for analysis 
(figure 1). The mean age (SD) was 55 (16) years (with a 
range of 18–88 years) of which 69 (51%) were men. The 
baseline and demographic characteristics of the cohort 
are summarised in table 1.
Of the 134 patients, 110 had a positive and 24 had a 
negative 18FDG PET-CT report. A malignant diagnosis was 
reported in 101 patients and a non-malignant diagnosis 
in 33 patients (table 2).
The sensitivity and specificity of PET-CT to correctly 
classify malignant disease for anterior mediastinal masses 
were 83% (95% CI 74 to 89) and 58% (95% CI 37 to 78), 
respectively, and the corresponding positive and negative 
predictive values were 90% (95% CI 83 to 95) and 42% 
(95% CI 26% to 61%), respectively (table 2).
Data from SUVmax were available in 96 patients and 
the calculated ROC area under the curve was 0.63 (95% 
CI 0.45 to 0.79) (figure 2).
dIsCussIOn
The results of our study, to our knowledge, are the largest 
to date (essential to ensure narrow CIs for estimates), 
and suggest that 18FDG PET-CT is moderately useful to 
rule out the diagnosis of malignancy when the test result 
is negative (good sensitivity), however, it is not able to rule 
in the diagnosis of malignancy when the result is positive.
Once an anterior mediastinal mass is diagnosed on 
imaging, downstream management is predicated on the 
risk of malignancy to stratify patients for management, 
with high-risk patients assigned to invasive biopsy or 
surgery, intermediate-risk patients assigned to surveil-
lance and low-risk patients assigned to discharge. In a 
recent survey, up to 50% of centres reported the use of 
PET for this purpose.
Table 1 Demographic characteristics of the cohort and 
diagnosis classification per histology report
(n=134)
Mean age (SD) 55 (16)
Male, n (%) 69 (51)
Histology
  Benign, n (%) 33 (25)
   Thymic hyperplasia 10 (8)
   Thymic cyst 8 (6)
   No malignancy 15 (11)
  Malignant, n (%) 101 (75)
   Thymoma 55 (41)
   Other malignant tumours 38 (28)
   Thymic carcinoma 8 (6)
Table 2 Diagnostic test performance for PET-CT evaluation 
of malignancy in an anterior mediastinal mass
18FDG PET-CT 
positive
18FDG PET-CT 
negative
Benign histology 19 14
Malignant histology 91 10
Test performance (with 95% CI)
  Sensitivity 82.7 74.3 to 89.3
  Specificity 58.3 36.6 to 77.9
  Positive predictive value 90.1 82.5 to 95.1
  Negative predictive 
value
42.4 25.5 to 60.8
FDG, fluorodeoxyglucose; PET, positron emission tomography. 
Figure 2 Receiver operating characteristic (ROC) plot of 
SUVmax versus malignancy.
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In published cohort series, it was reported that thymic 
tumours represent 50% of anterior mediastinal lesions, 
followed by lymphomas (25%) and less commonly a 
mixture of other aetiologies such as teratoma.3 A defin-
itive diagnosis can only be achieved after invasive biopsy4 
or surgical resection. The reported specificity of fine 
needle aspiration is limited (57%–82%)5–7 and the diag-
nostic values of CT and PET are not well known as few 
studies have been conducted and with very small sample 
sizes, typically less than 60.8 Decisions regarding direct 
surgical resection of anterior mediastinal masses can 
be challenging as the morphological features of thymic 
lesions overlap and a definite differentiation between 
histological subtypes of thymic pathology by CT can be 
difficult.9 10 Previous studies have shown promising results 
for SUVmax values in the differentiation between malig-
nant and benign lesions.11 However, the results of our 
analyses suggested that discrimination by SUVmax was 
relatively poor.
With moderately high sensitivity, the results from our 
study suggest that 18FDG PET-CT has moderate utility to 
ruling out malignancy in patients where the test is nega-
tive. There is still an appreciable proportion (17%) test 
negative despite the presence of disease. From a clinical 
perspective, it remains to individual judgement whether 
this is an acceptable proportion that balances against the 
consequences of missing a potentially invasive tumour.
It is difficult to define the clinical utility when faced 
with an ‘abstract’ figure for sensitivity of 83%; to help 
clinicians understand how this would fit in the clinical 
setting, it would be pertinent to look at more developed 
guidelines on perceived clinical utility of 18FDG PET-CT 
for the solitary pulmonary nodule to assess cancer 
risk. The results from a 2008 meta-analysis12 reported 
a sensitivity of 95% for PET to diagnose malignancy 
in pulmonary nodules, considerably higher than 83% 
for anterior mediastinal mass. Despite higher levels 
of sensitivity, there is still a reluctance for experts to 
discharge a patient with a negative 18FDG PET-CT, as in 
the 2013 American College of Chest Physicians guide-
lines13 the authors recommended serial CT monitoring 
when the 18FDG PET-CT is negative despite low clinical 
probability of lung cancer.
Currently, there are no established risk models for 
malignancy in anterior mediastinal masses, and there-
fore numeric quantification of risk is not possible. In the 
circumstance where the pretest probability for malig-
nancy is very low (eg, if the CT appearance suggests 
diffuse enlargement of the thymus only) then it would 
be reasonable to reassure the patient (a negative 18FDG 
PET-CT would not alter clinical management). If the 
pretest probability is very high (eg, a large lobulated 
mass in anterior mediastinum) it would be reasonable 
to proceed to invasive biopsy or resection (a negative 
18FDG PET-CT would not reassure). In the most diffi-
cult subgroup where the pretest probability for malig-
nancy is intermediate, given that serial CT imaging is 
recommended for lung cancer (despite sensitivity of 
95%) then it would be reasonable to default to the time 
tested method of screening for growth by CT for ante-
rior mediastinal masses as well. If that is the case, then 
there is clearly no clinical utility for 18FDG PET-CT (a 
negative test does not prevent serial CTs and a positive 
test is not reliable to rule in malignancy).
The limitation of our study, aside from that associated 
with retrospective conduct, is that we did not include 
the entire spectrum of the anterior mediastinal masses, 
in particular the small masses that were only kept under 
surveillance or discharged. On the other hand, we have 
included the larger lesions that are more worrying and 
in whom 18FDG PET-CT is usually requested. We were 
able to obtain an estimate of test performance relatively 
quickly through an established research collaborative 
as prospective conduct of a validation study is likely to 
require significant funding, more centres and time as 
anterior mediastinal lesions are not common. Certainly, 
we would welcome and encourage international efforts 
to address this important issue, ideally with reference of 
clinical effectiveness and cost-effectiveness.
COnClusIOns
18FDG PET-CT is moderately useful to rule out the 
diagnosis of malignancy when the test result is nega-
tive (good sensitivity), however, it is not able to rule in 
the diagnosis of malignancy when the result is positive 
(poor specificity). At the existing levels of sensitivity a 
negative test is insufficient to reassure and obviate the 
need for serial CT surveillance of indeterminate masses 
in the anterior mediastinum. Therefore, we conclude 
that 18FDG PET-CT does not have a role in routine 
clinical practice to assess the malignant potential of an 
anterior mediastinal mass.
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